KOLOA, Hawaii — Results showed use of Zynrelef as part of a multimodal analgesia protocol may significantly reduce pain and opioid use after total knee arthroplasty. “Zynrelef [bupivacaine and ...
A reduction in opioid usage over the entire treatment period was observed in patients treated with MR-107A-02 vs placebo. Topline data were announced from two phase 3 studies evaluating MR-107A-02 for ...
PITTSBURGH, May 8, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive results from its Phase 3 program of the novel fast-acting formulation of ...
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of the fixed-dose combination of bupivacaine and meloxicam (Zynrelef) for the ...
Meloxicam is an enolcarboxamide with preferential COX-2 inhibitory activity. In vitro studies with human tissues have confirmed the high affinity of meloxicam for COX-2, whereas COX-1 was inhibited ...
Symbravo is not substitutable with other formulations of meloxicam or rizatriptan. The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback